Global Vivacor/COREG/COREG CR Drug Insights Report 2016 - Research and Markets

Edit Business Wire 04 Apr 2016
Vivacor/COREG/COREG CR - Drug Insights, 2016 highlights the Vivacor/COREG/COREG CR marketed details, pipeline status and the Global API Manufacturers along with the location. The report covers the Global Market Assessment of the Vivacor/COREG/COREG CR covering the total sales estimation and also provides the Vivacor/COREG/COREG CR sales performa ......

What Substances Can Cause Sleep Behaviors?

Edit About.com 28 Nov 2015
There are a variety of medications that can cause sleep behaviors, ranging from antidepressants to medications that treat Alzheimer’s disease ... Many of these affect muscle control during rapid eye movement (REM) sleep ... These prescription medications may include.Coreg (carvedilol)Inderal (propranolol)Lopressor or Toprol XL (metoprolol)Sorine (sotalol)Tenormin (atenolol)TimololTrandate (labetalol)Zebeta (bisoprolol) ... Source. ... Darien, IL ... ....

European Global Navigation Satellite Systems: From Invention to Market (GSA - European GNSS Agency)

Edit Public Technologies 09 Nov 2015
(Source. GSA - European GNSS Agency) ... 'These GSA-funded programmes have done very exceptional work,' said the European Commission's Christoph Kautz. He noted two reasons for this success ... Another innovative project is COREGAL, which is developing a GNSS receiver that can be used to estimate biomass ... COREGAL uses the Galileo E5 signal in an airborne receiver monitoring both direct and reflected signals to accurately estimate biomass....

GSA Talks Space Policy in Bavaria (GSA - European GNSS Agency)

Edit Public Technologies 27 Aug 2015
ASPHALT, PUMA, STON, and SX5 were FP7 projects enjoying great success, while E-KnoT, COREGAL, ERSAT EAV, FOSTERITS, GNSS.asia2, LARA, PARADISE, POSITION, and e-Airport are Bavarian participants successfully working under the H2020 initiative ... COREGAL-Combined Positioning-Reflectometry Galileo Code Receiver for Forest Management Development of an ......

Flamel Technologies Announces Departure of Senior Vice President of Business and Corporate Development (Flamel Technologies SA)

Edit noodls 08 Apr 2015
(Source. Flamel Technologies SA) Flamel Technologies Announces Departure of Senior Vice President of ... The company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™(phenylephrine hydrochloride) in the USA and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines for Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline....

Flamel Technologies Announces Departure of Senior Vice President of Business and Corporate Development

Edit Stockhouse 07 Apr 2015
LYON, FRANCE--(Marketwired - Apr 7, 2015) - Flamel Technologies S.A. (NASDAQ ... Lisi ... The company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™(phenylephrine hydrochloride) in the USA and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines for Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline ... ....

Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With LiquiTime(R) Guaifenesin

Edit Stockhouse 27 Mar 2015
Registration Trial in the United States to Be Performed in 2016 ... The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline ... ....

Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial with LiquiTime Guaifenesin (Flamel Technologies SA)

Edit noodls 27 Mar 2015
(Source. Flamel Technologies SA) Flamel Technologies Announces Positive Results of a First-in-Man ... The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline ... Phone....

Flamel Technologies Announces Fourth Quarter and Full Year Results of Fiscal Year 2014 (Flamel Technologies SA)

Edit noodls 19 Mar 2015
(Source. Flamel Technologies SA) Flamel Technologies Announces Fourth Quarter and Full Year ... AB ... Anderson ... The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline....

Flamel Technologies to Present at Two Upcoming Investor Conferences (Flamel Technologies SA)

Edit noodls 06 Mar 2015
(Source. Flamel Technologies SA) Flamel Technologies to Present at Two Upcoming Investor. Conferences ... The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline....

Flamel Technologies to Report Fourth Quarter of Fiscal Year 2014 Results (Flamel Technologies SA)

Edit noodls 06 Mar 2015
(Source. Flamel Technologies SA) Flamel Technologies to Report Fourth Quarter ... (NASDAQ ... 19th at 10.00 a.m ... The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline....

Flamel Technologies Announces Price Change for Bloxiverz

Edit Stockhouse 15 Jan 2015
LYON, FRANCE--(Marketwired - Jan 15, 2015) -  Flamel Technologies (NASDAQ ... The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline....

Flamel Technologies Announces Price Change For Bloxiverz (Flamel Technologies SA)

Edit noodls 15 Jan 2015
(Source. Flamel Technologies SA) Flamel Technologies Announces Price Change for. Bloxiverz ... The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline ... Safe Harbor....
×